BioSpace News Archive

Drug Development

AACR: The Weekend Losers According to Wall Street

Shares fell in several life sciences companies at the close of the market Friday on apparently lackluster early data from their respective research projects. We look into each one below:

April 11, 2022
·
4 min read
·
Vanessa Doctor, RN
AACR: The Weekend Winners - Amgen, Bicycle and BioNTech

Data presented at the AACR Annual Meeting over the weekend will likely lead to continued stock jumps for Amgen, Bicycle Therapeutics and BioNTech.

April 11, 2022
·
2 min read
·
Jazmine Colatriano, M.S.
mRNA in the Spotlight as BioNTech Finally Makes a Splash in Cancer

The science community is aware of the effectiveness of the mRNA vaccines developed by Moderna and Pfizer-BioNTech. Now, they may be using that technology to treat cancer.

April 11, 2022
·
5 min read
·
Mark Terry
Ansa Biotech Raises $68M to Launch Customizable DNA Synthesis Service

Ansa Biotechnologies is advancing towards the launch of a customizable DNA synthesis service, stemming from the development of a novel synthesis method.

April 11, 2022
·
2 min read
·
Jazmine Colatriano, M.S.
Career Advice

How to Prepare for Your Biopharma Job Search

To help alleviate some of the stress related to finding a new job, we’ve created a comprehensive guide detailing how to prepare for your biopharma job search.

April 11, 2022
·
3 min read
·
Editorial Team
Business

Better Together: New Licensing and Collaboration Deals to Watch

The week began with new partnerships formed in the life sciences industry as several firms entered into licensing deals and collaboration commitments. Here’s a look at the latest.

April 11, 2022
·
3 min read
·
Vanessa Doctor, RN
Business

Pfizer’s Bourla Touts New CFO’s “True Insights” into Healthcare System

Pfizer has found its replacement for longtime Chief Financial Officer Frank D’Amelio, who announced his retirement from the company five months ago.

April 11, 2022
·
2 min read
·
Alex Keown
Policy

Rethinking Boosters and Personal Responsibility as Pandemic Enters New Phase

The FDA is looking at revising the current vaccine strategy and emphasizing that individuals need to consider their own risk tolerance. For that and more, continue reading.

April 11, 2022
·
5 min read
·
Mark Terry
RNA, tRNA, circRNA: Just Imagine the Therapeutic Possibilities!

mRNA therapies are the future of treatments for many different conditions. Now, other types of RNA therapy are getting attention too, and it’s sparking exciting new developments.

April 11, 2022
·
3 min read
·
Hannah Chudleigh
Drug Development

Veru Soars as Oral Antiviral for COVID-19 Reduces Deaths by 55%

Veru posted positive interim Phase III data from its late-stage study assessing oral antiviral sabizabulin in hospitalized COVID-19 patients. Here’s more about it.

April 11, 2022
·
3 min read
·
Alex Keown